{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:06:40Z","timestamp":1780322800908,"version":"3.54.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.repc.2021.09.013","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:11:58Z","timestamp":1658218318000},"page":"693-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-1147","authenticated-orcid":false,"given":"Tiago","family":"Aguiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2021.09.013_bib0305","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2021.09.013_bib0310","first-page":"e558","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0315","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2021.09.013_bib0320","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0325","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","article-title":"Epidemiology of the inherited cardiomyopathies","volume":"18","author":"McKenna","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0330","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0335","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","volume":"42","author":"Maron","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/hrt.20.1.1","article-title":"Asymmetrical hypertrophy of the heart in young adults","volume":"20","author":"Teare","year":"1958","journal-title":"Br Heart J"},{"key":"10.1016\/j.repc.2021.09.013_bib0345","first-page":"221","article-title":"Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis","volume":"106","author":"Brock","year":"1957","journal-title":"Guys Hosp Rep"},{"key":"10.1016\/j.repc.2021.09.013_bib0350","first-page":"220","article-title":"Contribution \u00e0 l\u2019\u00e9tude des r\u00e9tr\u00e9cissements de l\u2019orifice ventriculo-aortique","volume":"3","author":"Vulpian","year":"1868","journal-title":"Arch Physio"},{"key":"10.1016\/j.repc.2021.09.013_bib0355","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000658-196108000-00003","article-title":"Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy","volume":"154","author":"Morrow","year":"1961","journal-title":"Ann Surg"},{"key":"10.1016\/j.repc.2021.09.013_bib0360","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.281.7.650","article-title":"Clinical course of hypertrophic cardiomyopathy in a regional United States cohort","volume":"281","author":"Maron","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2021.09.013_bib0365","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0370","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","article-title":"Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy","volume":"106","author":"Bos","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0375","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.amjcard.2014.01.435","article-title":"Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors","volume":"113","author":"Spirito","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0380","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2021.09.013_bib0385","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.repc.2021.09.013_bib0390","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1540-8167.2007.00965.x","article-title":"Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics","volume":"19","author":"Alcalai","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0395","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0400","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.repc.2021.09.013_bib0405","doi-asserted-by":"crossref","first-page":"12607","DOI":"10.1073\/pnas.1309493110","article-title":"Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human \u03b2-cardiac myosin motor function","volume":"110","author":"Sommese","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repc.2021.09.013_bib0410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1532-429X-13-3","article-title":"Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness","volume":"13","author":"R\u00fcssel","year":"2011","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.repc.2021.09.013_bib0415","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0420","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2021.09.013_bib0425","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0430","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.84.3.1188","article-title":"Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction","volume":"84","author":"Klues","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0435","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.amjcard.2007.10.032","article-title":"Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"101","author":"Harrigan","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0440","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/0735-1097(95)00390-8","article-title":"Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients","volume":"26","author":"Klues","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0470","doi-asserted-by":"crossref","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2021.09.013_bib0475","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12551-014-0153-3","article-title":"Surgery for hypertrophic cardiomyopathy","volume":"7","author":"Wu","year":"2015","journal-title":"Biophys Rev"},{"key":"10.1016\/j.repc.2021.09.013_bib0480","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1053\/euhj.2002.3285","article-title":"Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes","volume":"23","author":"Firoozi","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2021.09.013_bib0485","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/CIRCULATIONAHA.112.000849","article-title":"Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0490","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jcin.2008.07.005","article-title":"Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007","volume":"1","author":"Fernandes","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.repc.2021.09.013_bib0495","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00392-007-0616-7","article-title":"Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience","volume":"97","author":"Kuhn","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0500","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0505","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.repc.2021.09.013_bib0510","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.repc.2021.09.013_bib0515","doi-asserted-by":"crossref","first-page":"e7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repc.2021.09.013_bib0520","doi-asserted-by":"crossref","first-page":"e8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.repc.2021.09.013_bib0525","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1152\/ajpheart.00023.2020","article-title":"Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations","volume":"318","author":"Sparrow","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0530","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.repc.2021.09.013_bib0535","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.repc.2021.09.013_bib0540","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0545","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.repc.2021.09.013_bib0550","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","article-title":"Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy","volume":"62","author":"Kubo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0555","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2009.04.026","article-title":"Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia","volume":"54","author":"Kwon","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0560","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2021.09.013_bib0565","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11136-012-0182-y","article-title":"Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy","volume":"22","author":"Huff","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.repc.2021.09.013_bib0570","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.repc.2021.09.013_bib0575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11739-012-0866-x","article-title":"Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study","volume":"9","author":"Magr\u00ec","year":"2014","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.repc.2021.09.013_bib0580","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.repc.2021.09.013_bib0585","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM CMR substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.repc.2021.09.013_bib0590","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.repc.2021.09.013_bib0595","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/mcp.2010.0682","article-title":"Left atrial volume index predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction","volume":"86","author":"Patel","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.repc.2021.09.013_bib0600","doi-asserted-by":"crossref","first-page":"e001285","DOI":"10.1161\/JAHA.114.001285","article-title":"Left ventricular mass and the risk of sudden cardiac death: a population-based study","volume":"3","author":"Laukkanen","year":"2014","journal-title":"J Am Heart Assoc"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S087025512200261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S087025512200261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:31Z","timestamp":1760109091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S087025512200261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S087025512200261X"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2021.09.013","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}